Rezafungin Production Cost Reports

The report provides a detailed analysis essential for establishing a rezafungin production plant. It encompasses all critical aspects necessary for rezafungin production, including the cost of rezafungin production, rezafungin plant cost, rezafungin production costs, and the overall rezafungin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a rezafungin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Rezafungin is used for treating adults with candidemia and invasive candidiasis caused by Candida species. It is used when other antifungal options are inadequate or unsuitable. This includes bloodstream infections and deep tissue infections from common strains like C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and some resistant types like C. auris.

It only requires once-weekly intravenous dosing compared to daily for echinocandins like caspofungin. It shows non-inferiority with around 60% success rates at day 14, making it valuable for severely ill patients in hospital settings. It is also utilised in the outpatient management of azole-resistant mucocutaneous infections, osteomyelitis, and adjunctive therapy for pulmonary aspergillosis. Its common side effects include fever, diarrhoea, anaemia, nausea, vomiting, abdominal pain, constipation, and low blood levels of potassium, magnesium, or phosphate.

The rezafungin market is influenced by rising candidemia and invasive candidiasis cases in immunocompromised patients. The growing antifungal resistance, along with its once-weekly dosing convenience over other medication boosts its market. The FDA and EMA approvals and growth into paediatrics and aspergillosis in the expanding antifungal sector contribute to its demand.

The high per-dose costs that require patient access discounts and reduced administration frequency influence industrial rezafungin procurement. Other factors like fewer IV days, benefits over daily alternatives, along with API sourcing from specialised suppliers that influence hospital formulary placement and bulk purchasing impacts its sourcing strategies.

Raw Material for Rezafungin Production

According to the rezafungin production plant project report, the key raw materials used in the production of rezafungin include Aspergillus nidulans strain, fermentation nutrients, and solvents.

Production Process of Rezafungin

The extensive rezafungin production cost report consists of the following major industrial production process:

1. By Fermentation: The production process of rezafungin involves a semi synthetic process. First, echinocandin B is first produced by fermenting Aspergillus nidulans in a controlled fermentation medium. This is then extracted from the biomass with solvents like methanol or acetone and purified. Then Echinocandin B is enzymatically deacylated with a deacylase to give the echinocandin core, which is acylated with the chemically prepared 4'' (pentyloxy) [1,1':4',1'' terphenyl] 4 carboxylic acid side chain to form an anidulafungin type intermediate. This intermediate is finally modified at the ornithine hemiaminal position with a choline type aminal ether and converted to the acetate salt by treatment with acetic acid, giving rezafungin acetate as the final product.

Rezafungin has the molecular formula of C63H85N8O17 with a molecular weight of 1226.4 g/mol. It exists as a powder and is concentrated in 200 mg vials that require reconstitution for IV infusion. It shows high protein binding, low clearance, a volume of distribution of 67 L, and a prolonged terminal half-life of 127-146 hours. This has the XLogP3-AA value of 2.9, with 13 hydrogen bond donors, 17 acceptors, 18 rotatable bonds, topological polar surface area of 366 Ų. It is stable with enhanced solubility compared to predecessors. It goes through metabolism via side-chain hydroxylation and O-dealkylation to despentyl-rezafungin. It retains activity while inhibiting fungal 1,3-β-D-glucan synthase.